You are here: Industry Insights > BMS

News List

BMS acquires biopharma firm MyoKardia for $13.1bn pharmaceutical-technology
November 19, 2020
Bristol Myers Squibb (BMS) has completed its acquisition of clinical-stage biopharma firm MyoKardia in an all-cash transaction for $13.1bn.
BMS collaborates with insitro to develop drugs for ALS pharmatimes
October 30, 2020
Bristol Myers Squibb has signed a five-year collaboration agreement with machine learning specialist insitro to develop drugs for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.
BMS partners with Sensyne Health for rare blood disease research pharmatimes
October 26, 2020
Clinical AI company Sensyne Health has signed a research collaboration agreement with Bristol Myers Squibb to apply machine learning for rare blood disease research.
BMS to acquire biopharma firm MyoKardia for $13.1bn pharmaceutical-technology
October 10, 2020
Bristol Myers Squibb (BMS) has signed a definitive merger agreement to acquire clinical-stage biopharma firm MyoKardia, in a cash-based transaction valued at $13.1bn.
BMS’ Opdivo combo gets FDA approval for malignant pleural mesothelioma pharmaceutical-technology
October 10, 2020
The US Food and Drug Administration (FDA) has approved Bristol Myers Squibb (BMS)’s Opdivo (nivolumab) plus Yervoy (ipilimumab) for treating adults with unresectable malignant pleural mesothelioma (MPM).
Pfizer, BMS' Eliquis tops Xarelto, vitamin K drugs for site-specific bleeding risks in French real-world study fiercepharma
September 01, 2020
Pfizer and Bristol Myers Squibb's anticoagulant superstar Eliquis has raced out to blockbuster sales in recent years and a big-time lead over its its warfarin alternative competitors.
BMS signs $475m licensing deal with Dragonfly Therapeutics pharmaceutical-technology
August 19, 2020
Bristol Myers Squibb (BMS) has signed an agreement for an exclusive worldwide licence to Dragonfly Therapeutics’ interleukin-12 (IL-12) investigational immunotherapy programme.
BMS’ Opdivo improves survival in gastric and oesophageal cancers pharmatimes
August 13, 2020
Bristol Myers Squibb has revealed the results from the Phase III CheckMate-649 evaluating Opdivo (nivolumab) plus chemotherapy in first-line metastatic gastric cancer, gastroesophageal junction (GEJ) cancer or oesophageal adenocarcinoma.
FDA refuse to file BMS/bluebird bio's CAR-T therapy pharmatimes
May 14, 2020
US regulators have refused to file Bristol Myers Squibb and bluebird bio's marketing application seeking approval of idecabtagene vicleucel (ide-cel) for patients with heavily pre-treated relapsed and refractory multiple myeloma.
BMS' ZEPOSIA Wins Approval for RMS contractpharma
March 30, 2020
Oral medication offers RMS patients an initiation with no genetic test and no label-based first-dose observation required.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 15 16 Next page